Post-ABVD/pre-radiotherapy 18F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: A retrospective analysis on 165 patients

Patrizia Ciammella, Andrea Riccardo Filippi, Gabriele Simontacchi, Michela Buglione, Barbara Botto, Monica Mangoni, Cinzia Iotti, Francesco Merli, Luigi Marcheselli, Gianni Bisi, Umberto Ricardi, Annibale Versari

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the prognostic role of both interim fluorine-18 fludeoxyglucose positron emission tomography (i-18F-FDG-PET) and end-of-chemotherapy fluorine-18 fludeoxyglucose positron emission tomography (eoc-18F-FDG-PET) in patients with early-stage Hodgkin lymphoma (HL). Methods: We screened 257 patients with early-stage HL treated with combined modality therapy between March 2003 and July 2011. All were staged using fluorine-18 fludeoxyglucose positron emission tomography (18F-FDGPET) before chemotherapy and after two doxorubicin, bleomycin, vinblastine and dacarbazine cycles (i-18F-FDGPET); 165 patients were also evaluated by 18F-FDG-PET at the end of chemotherapy (eoc-18F-FDG-PET). Results: After revision, 85% of patients were negative for i-18F-FDG-PET and 15% were positive. After eoc-18F-FDGPET revision, 23 patients had a positive scan. The median follow-up was 56 months. The 5-year overall survival (OS) and progression-free survival (PFS) for the whole cohort were 97.5% and 95.6%, respectively. For i-18F-FDGPET-negative and i-18F-FDG-PET-positive patients, the 5-year PFS rates were 98% and 84%, respectively; for eoc-18F-FDG-PET-negative and eoc-18F-FDG-PET-positive patients, the 5-year PFS rates were 97% and 78%, respectively. Combining the i-18F-FDG-PET and eoc-18F-FDGPET results, the 5-year PFS were 97%, 100% and 82% in negative/negative, positive/negative and positive/positive groups, respectively. The 5-year OS rates were 98% and 83% in eoc-18F-FDG-PET-negative and eoc-18F-FDG-PET-positive patients, respectively; the 5-year OS was 98%, 100% and 83% in negative/negative, positive/negative and positive/ positive groups, respectively. Conclusion: This study provides additional information on the prognostic role of i-18F-FDG-PET and eoc-18FFDG-PET in early-stage HL. As data are accumulating and the clinical scenario is rapidly evolving, we might need to rethink the use of 18F-FDG-PET as a prognostic marker for early-stage HL in the near future.

Original languageEnglish
Article number20150983
JournalBritish Journal of Radiology
Volume89
Issue number1061
DOIs
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Post-ABVD/pre-radiotherapy <sup>18</sup>F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: A retrospective analysis on 165 patients'. Together they form a unique fingerprint.

  • Cite this